Sage Journals: Discover world-class research

Abstract

Aims

Low-density lipoprotein cholesterol predicts cardiovascular events in patients with diabetes. However, it is uncertain whether serum triglycerides level is also associated with an occurrence of future cardiovascular events in diabetic patients. We aimed to test whether serum triglycerides is associated with first cardiovascular events in diabetic patients.

Methods and results

We recruited 5042 participants with diabetes mellitus from the standard versus intEnsive statin therapy for hypercholesteroleMic Patients with diAbetic retinopaTHY (EMPATHY), multicenter, prospective, randomized, open-label, blinded-endpoint study. Median follow-up was three years. We evaluated an association of serum triglycerides with first cardiovascular events in cox-regression hazard models adjusted by age, sex, hypertension, current smoking, low-density lipoprotein cholesterol, and body mass index. Cardiovascular events were defined as (a) major adverse cardiac events including myocardial infarction, stroke, or cardiac death; and (b) cardiovascular diseases including myocardial infarction, unstable angina, ischemic stroke, or large artery disease or peripheral arterial disease. Serum triglycerides were associated with major adverse cardiac events (adjusted hazard ratio: 1.021 per 10 mg/dl; 95% confidence interval: 1.007–1.035; p = 0.0025) and cardiovascular diseases (adjusted hazard ratio: 1.023 per 10 mg/dl; 95% confidence interval: 1.013–1.034; p = 0.0000077). Comparing the top quintile (>185 mg/dl) with the bottom quintile (<79 mg/dl), the adjusted hazard ratio increased 1.89 (95% confidence interval: 1.03–2.80, p = 0.04) for major adverse cardiac events, and 1.90 (95% confidence interval: 1.18–3.07, p = 0.007) for cardiovascular diseases. There were no overall interactions of triglycerides and treatment assignment (standard/intensive statins) on both outcomes (p-trend = 0.33 for major adverse cardiac events, p-trend = 0.62 for cardiovascular diseases).

Conclusions

Serum triglycerides were associated with first cardiovascular events among high-risk diabetes patients with hypercholesterolemia and retinopathy.

Keywords

Triglycerides cardiovascular disease statin residual risk

Get full access to this article

View all access options for this article.

References

Kannel

. Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study. Am Heart J 1985; 110: 1100–1107.

Xie

Ikram

Cotch

et al.

Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease: A systematic review and meta-analysis. JAMA Ophthalmol 2017; 135: 586–593.

Teramoto

Sasaki

Ishibashi

et al.

Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan–2012 version. J Atheroscler Thromb 2014; 21: 296–298.

Catapano

Graham

De Backer

et al.

2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37: 2999–3058.

Ueshima

Itoh

Kanazawa

et al.

Rationale and design of the standard versus intensive statin therapy for hypercholesterolemic patients with diabetic retinopathy (EMPATHY) study: A randomized controlled trial. J Atheroscler Thromb 2016; 23: 976–990.

Itoh

Komuro

Takeuchi

et al.

Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolaemia and diabetic retinopathy: Report of a randomised study. Diabetes Care 2018; 41: 1275–1284.

Collins

Armitage

Parish

et al.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005–2016.

Colhoun

Betteridge

Durrington

et al.

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–696.

Reith

Armitage

. Management of residual risk after statin therapy. Atherosclerosis 2016; 245: 161–170.

10.

Austin

Rodriguez

McKnight

et al.

Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol 2000; 86: 412–416.

11.

Sharrett

Ballantyne

Coady

et al.

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 1108–1113.

12.

Miller

Cannon

Murphy

et al.

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008; 51: 724–730.

13.

Schwartz

Abt

Bao

et al.

Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol 2015; 65: 2267–2275.

14.

DeLong

Clarke-Pearson

. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44: 837–845.

15.

Ferrari

Aguiar

Alegria

et al.

Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl 2016; 18: C2–C12.

16.

Reiner

. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol 2017; 14: 401–411.

17.

Reiner

. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update. Nutr Metab Cardiovasc Dis 2013; 23: 799–807.

18.

Sacks

Hermans

Fioretto

et al.

Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: A global case-control study in 13 countries. Circulation 2014; 129: 999–1008.

19.

Tada

Kawashiri

Nohara

et al.

Lipid management in a Japanese community: Attainment rate of target set by the Japan Atherosclerosis Society Guidelines for the prevention of atherosclerotic cardiovascular diseases 2012. J Atheroscler Thromb 2017; 24: 338–345.

20.

Faergeman

Holme

Fayyad

et al.

Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009; 104: 459–463.

21.

Willer

Schmidt

et al.

Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013; 45: 1345–1352.

22.

Liu

Peloso

et al.

Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet 2017; 49: 1758–1766.

23.

Yokoyama

Origasa

Matsuzaki

et al.

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090–1098.

24.

Elam

Ginsberg

Lovato

et al.

Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2017; 2: 370–380.

25.

Kubota

Iso

Yamagishi

et al.

JPHC Study Group. Daily total physical activity and incident stroke: The Japan public health center-based prospective study. Stroke 2017; 48: 1730–1736.

26.

Bonaventure

Kurth

Pico

et al.

Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: The Three-City Study. Atherosclerosis 2010; 210: 243–248.

27.

Wieberdink

Poels

Vernooij

et al.

Serum lipid levels and the risk of intracerebral hemorrhage: The Rotterdam Study. Arterioscler Thromb Vasc Biol 2011; 31: 2982–2989.

28.

Kramer

Rodrigues

Canani

et al.

Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: Meta-analysis of observational studies. Diabetes Care 2011; 34: 1238–1244.

29.

Nordestgaard

Benn

Schnohr

et al.

Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299–308.

30.

Nordestgaard

Langsted

Mora

et al.

Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points–a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016; 37: 1944–1958.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.19 MB

Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy

Abstract

Aims

Methods and results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material